Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05883293 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of Allogeneic Fat Decellularized Active Protein in the Treatment of Pulmonary Fibrosis

Study acronym: CEFFE-PF
StatusActive, Not Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2025 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 31, 2024 to Aug 31, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v3
  2. Start date changed from estimate of Jun 1, 2023 to Aug 14, 2023v2 Show 4 more changesShow less
    • Eligibility criteria expanded, about 59 words
    • Secondary endpoints: 5 to 16
    • Study description expanded, about 7 words
    • Study title shortened, about 1 word
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to investigate the efficacy and safety of allogeneic adiphatic cyclic active protein in the treatment of pulmonary fibrosis. The main questions it aims to answer are: 1. Efficacy of allogeneic adiposeactive protein in the treatment of pulmonary fibrosis 2. Safety of allogeneic fat respiration active protein in the treatment of pulmonary fibrosis. A total of 7 participants will be enrolled. Participants will be asked that they will receive 2ml of each nebulized inhalation Cell Free Fat Extract (CEFFE), inhaled every 3 days, for a total of 7 nebulized inhalation treatments. The clinical trial was designed using a single-center, self-controlled trial with no control group and no blinding.
Trial Details
NCT Number NCT05883293
Lead Sponsor Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Conditions
(from sponsor)		 Pulmonary Fibrosis
Related terms Pulmonary Fibrosis
Enrollment 7 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov